Cardiogen

What is it?

Cardiogen is a Khavinson bioregulator peptide targeting cardiomyocytes — claimed, like the rest of the family, to modulate gene expression for cardiac contractility and tissue maintenance. It’s part of the vascular/cardiovascular corner of the Khavinson short-peptide bioregulator family, alongside Vesugen.

What does it do in my body?

Like the rest of the Khavinson family, Cardiogen’s claimed mechanism is that a short tissue-derived peptide crosses cell and nuclear membranes, binds DNA promoter regions, and modulates transcription in a tissue-specific way — here, in cardiac tissue. There is no Cardiogen-specific mechanism data beyond this general family-level theoretical claim; the family’s underlying nuclear-penetration mechanism has in-vitro support (Fedoreyeva et al. 2011, Biochemistry (Mosc), 22117547), but that work was not done on Cardiogen specifically.

How can it help me?

• Where the science stands: Directory lists “Moderate” (12 studies, 9 human) — but the 9 human studies are a citation-mismatch, not real peptide evidence. Actual base: preclinical/anecdotal

The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.

Is it dangerous? What are the side effects?

No Cardiogen-specific adverse-event data exists. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.

The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and Cardiogen’s thin evidence base makes it an even easier target for mislabeling since there’s little independent literature to check a seller’s claims against. Third-party COA verification matters more here than for almost any other peptide class.

Regulatory status: Cardiogen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance. Unlike Thymalin, Cardiogen holds no clinical-use approval anywhere.

Part 1 — How to reconstitute it

What's used: bacteriostatic water (sterile, preserved water the powder is mixed with) and a separate, larger reconstitution syringe used only for mixing — not the small syringe used for administration.

The exact bacteriostatic-water volume and resulting concentration for Cardiogen are covered in the dosing notes and the deeper-science view. The right volume depends on the vial size.

How it's mixed

• The vial is tilted and the bacteriostatic water is added slowly down the inside glass wall — not squirted straight onto the powder.
• It is swirled gently to dissolve. It is never shaken — shaking can damage the peptide.
• The reconstituted vial is stored refrigerated and out of light.
• Reconstituted peptides are commonly used within a few weeks, inside the beyond-use window the source specifies — that window varies by peptide.

The free reconstitution calculator does the concentration math for any vial size and water volume, including the equivalent units on an insulin syringe.

Part 2 — Typical dosing

Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.

Administration as reported. Reported practice is subcutaneous administration (into the fat just under the skin) using a 0.3 mL U-100 insulin syringe, with sites rotated.

Educational purposes only — this reflects what the Russian-school protocol convention and the peptide community actually use, stated plainly; it is not medical advice.

There is no Western-validated dosing protocol for Cardiogen, and — unlike some other provisional members — no meaningful clinical or community dosing record either, given the thin evidence base. What exists is only the generic Khavinson-family cycle pattern:

• Cycle structure: a short course — typically 10–20 consecutive days — followed by a long rest, repeated 2–3 times per year, per the broader family convention.
• Dose: synthetic Khavinson short peptides generally converge around ~100–200 mcg/day over the cycle, but no Cardiogen-specific dose-finding data exists to confirm this applies here.
• Storage: lyophilized powder is stable cold; once reconstituted with bacteriostatic water, refrigerate and use within roughly 28 days.

Treat any specific number for Cardiogen as generic family convention, not peptide-specific validated dosing.

Turning milligrams into syringe units. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. At a concentration of C mg/mL, a dose of D mg = D ÷ C mL = (D ÷ C) × 100 units. Example: at 5 mg/mL, a 0.5 mg dose = 0.1 mL = 10 units. The exact units depend on the vial's mg and the water volume used.

What should I avoid combining — and what's synergistic?

Cardiogen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.

Where do people source this?